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Abstract
Purpose We examined distress levels, problems, referral wish, and supportive health care use in a cross-sectional group of 
breast cancer survivors at two-time points with a 1-year time interval. Also, factors related to continuing elevated distress 
were explored.
Methods Breast cancer survivors, 1–5 years after chemotherapy completion, filled in the Dutch Distress Thermometer/
Problem List (DT/PL) and questions on background characteristics at study inclusion (T1). DT/PL responses and health 
care use were discussed during semi-structured interviews. One year later, re-assessment took place (T2). The data were 
analyzed by descriptive and univariate analyses. Continuing elevated distress was defined as a DT score ≥ 5 at T1 and T2.
Results Seventy-three survivors completed all questionnaires (response = 84.6%). Eighteen (25%) experienced continuing 
elevated distress. Fatigue (T1 N = 48 (66%); T2 N = 41 (56%)) and lack of physical fitness (T1 N = 44 (60%); T2 N = 36 (49%)) 
were most often reported. Time since diagnosis, health care use, and practical, social, emotional and physical problems 
were significantly associated with continuing elevated distress. Between diagnosis and T1, N = 49(67%) used supportive 
healthcare services, mostly a psychologist and/or a physical/lymphedema therapist, and between T1 and T2, 39 (53%) did. 
At T1, 8 (11%) expressed a referral wish and at T2, 11 (16%) did.
Conclusions Screening and management of distress, problems, and referral wish are important, even years after chemotherapy 
completion as a substantial proportion of breast cancer survivors continue to report elevated distress and problems. Special 
attention should be paid to survivors reporting physical problems, especially fatigue and lack of physical fitness, since these 
problems are most strongly related to continuing elevated distress.
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 Introduction
Breast cancer is the most prevalent cancer in women world-
wide [1]. Due to earlier diagnosis and advances in treatment, 
the 5-year survival rate of breast cancer increased from 74 to 
88% between 1981 and 2015 in the Netherlands [2]. With the 
growing number of breast cancer survivors, understanding of 
not only physical but also psychosocial functioning beyond 
diagnosis and treatment is essential for optimal survivorship 
care for this population.
Receiving a diagnosis of cancer and undergoing treatment 
pose challenges to survivors’ coping abilities. Survivors can 
experience tumor- or treatment-related physical difficulties 
such as fatigue, insomnia, and sexuality-related problems, 
and these problems may persist into longer-term survivor-
ship [3–6]. Additionally, they may face emotional, social, 
spiritual, and/or practical problems [7–9].
The problems patients experience altogether are often 
referred to as “distress” [10]. According to the transactional 
model of stress and coping of Lazarus and Folkman (1984), 
distress arises when an individual appraises that the demands 
of the stressor (e.g., cancer) exceed personal resources 
(the survivor’s ability to cope with cancer) [11]. Distress 
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has been associated with reduced health-related quality of 
life [12, 13], low satisfaction with medical care [14], and 
decreased treatment adherence [15]. Distress seems tran-
sient for most cancer survivors, but 15–21% of the survivors 
report stable high levels of distress up to 15-month post-
diagnosis [16, 17]. Consequently, it has been recommended 
to routinely screen for distress in cancer survivors to detect 
problems for which referral may be indicated. The National 
Comprehensive Cancer Network (NCCN, US) guideline for 
distress management was the first to recommend to screen 
all cancer patients with the Distress Thermometer (DT), 
a questionnaire specifically developed for cancer patients 
[10]. The NCCN also advises to use a Problem List (PL) 
that investigates which problem(s) in the practical, social, 
emotional, spiritual, and/or physical domain underlie the 
reported level of distress. The DT in combination with the 
PL has a good reliability and internal consistency [18]. 
A meta-analysis including 42 studies from 20 countries, 
including 14,808 cancer patients varying in cancer and treat-
ment type, showed that the DT is a highly useful and valid 
screening tool to detect distress [19].
The Dutch guideline on screening and monitoring dis-
tress describes a process that encompasses (1) completion 
of the Dutch version of the DT/PL, including a question on 
referral wish, (2) discussion of the completed DT/PL with 
patients, and (3) referral to appropriate healthcare services 
if needed or wished [20]. Following the stress-coping model 
of Lazarus and Folkman, survivors should be approached 
on how to optimize their ability to cope and reduce their 
burden. The Dutch guideline describes a process that is in 
line with this stress-coping approach. Adequate referral to 
supportive health care services after exploring survivors’ 
referral wish can aid in enhancing effective coping strategies 
and reducing the burden of the problems experienced [20]. 
Also, a screening process coupled with discussion and refer-
ral according to pre-determined pathways showed to be more 
effective with respect to doctor-patient communication and 
number of referrals than a screening process without these 
components [21–23].
Although the DT/PL has been recommended as the pre-
ferred tool for screening [24], little is known about DT/PL 
responses of breast cancer survivors who are beyond the first 
year after completion of primary treatment, i.e., longer-term 
cancer survivors. Samples often include a mixture of survi-
vors who are within the first year after primary treatment 
(re-entry phase [6]), long-term survivors (5+ years after 
diagnosis [25]), and survivors who are in between (longer- 
term survivors). This makes it difficult to gain insight into 
the severity of distress, nature of problems, and referral wish 
of longer-term survivors [26–28]. Additionally, several stud-
ies examined the course of distress over time in breast cancer 
survivors who were within the first 15 months after diagno-
sis [17, 29]. However, no studies are known assessing DT/
PL responses over time in longer-term (breast) cancer survi-
vors. As longer-term breast cancer survivors may suffer from 
lingering emotional and physical problems (e.g., [3]), lon-
gitudinal studies may provide important information about 
the prevalence of distress and the underlying problems over 
time. Also, knowledge about supportive health care use and 
referral wish can further increase insight into their needs.
The present study aims to contribute to our understand-
ing of (clinically elevated) distress levels, problems, refer-
ral wish and health care use in longer-term breast cancer 
survivors over a 1-year time period. Moreover, we explored 
which sociodemographic and illness-related variables and 




Survivors were recruited from the outpatient clinic of the 
Department of Medical Oncology of the University Medical 
Center Groningen (UMCG). Female breast cancer survivors 
who consecutively visited their medical oncologist for a rou-
tine follow-up visit and who had completed adjuvant chemo-
therapy 1–5 years earlier were invited to participate (longer- 
term survivors). Eligibility criteria were the following: age 
≥ 18 years, stage I–III breast cancer, no recurrent cancer, 
physically and cognitively able to complete a questionnaire 
and be interviewed, and sufficiently fluent in Dutch. The 
study was approved by the medical ethical committee of 
the UMCG.
 Procedures
Eligible survivors received a letter at home with informa-
tion about study aims and procedures, the questionnaire, 
an informed consent form, and contact information of the 
investigators, 1 week before the routine follow-up visit. 
Survivors deciding to participate were requested to return 
the completed informed consent form and questionnaire in a 
prepaid return envelope to the UMCG before the visit (T1). 
Informed consent was obtained from all individual survi-
vors included in the study. Immediately after the routine 
follow- up visit, enrolled survivors received a semi-structured 
interview (± 20 min) with a specially trained oncology nurse 
or research psychologist in which responses on the DT/PL 
were discussed; brief psycho-education was provided (in 
case of problems); the need for a referral to additional sup-
portive care services was explored and supportive health 
care use since diagnosis was assessed (first cross-sectional 
assessment; T1). Single sessions (e.g., intake) with a health 
care professional were not considered as care. Survivors 
Support Care Cancer (2020) 28: –303230233024
1 3
expressing a referral wish were referred to a relevant health 
care professional or were instructed how to access the health 
care service that was requested.
The DT/PL was sent to participating survivors 1 year later 
together with an invitation for a second interview (second 
cross-sectional assessment; T2). Survivors who forgot to 
return the DT/PL or who were not scheduled for a follow-up 
visit (to a medical, surgical, or radiation oncologist) 1 year 
later were offered an interview by telephone. Up to three 
attempts by phone were made to contact survivors who did 
not return the DT/PL.
 Measures
Self-report questions assessed the following socio- 
demographic characteristics at T1: age, marital status, pres-
ence of children, educational level (range: primary (1) to 
university (6)), and employment status (employed for wages; 
not-employed). Illness-related characteristics (date of diag-
nosis, pTNM-classification, cancer stage (I–III, derived 
from pTNM-classification), medical treatment, and date of 
completion of last chemotherapy cycle were collected from 
the survivors’ medical records.
Distress, problems, and referral wish were measured 
using the Dutch DT/PL [8, 10], at T1 and T2. The DT 
consists of a single item that asks cancer survivors to 
indicate the amount of overall distress experienced during 
the past week on an 11-point scale (0–10; no to extreme 
distress). The Dutch DT/PL has been validated for cancer 
patients with different diagnoses and treatments [8, 9]. 
A DT cutoff score of ≥ 5 represents clinically elevated 
distress in Dutch breast cancer survivors. The sensitivity 
was 0.85, specificity 0.66, positive predictive value 0.32, 
and negative predictive value 0.96 [9]. On the 47-item PL, 
cancer survivors can indicate whether or not (yes/no) they 
experienced practical, family/social, emotional, religious/
spiritual, and physical problems. Survivors were asked to 
rate from 1 to 10 the amount of distress they experienced 
for each item in the PL they answered “yes.” Internal 
consistency and reliability of the PL is good (Cronbach’s 
alpha = 0.90). Lastly, the questionnaire assesses cancer 
survivors’ referral wish (yes, maybe, or no) to a health 
care professional (psychologist, social or pastoral worker, 
oncology nurse, physical therapist, or dietician), peer sup-
port from a fellow patient, and/or to other types of health 
care [8].
During the interview at T1 and T2, patients were asked 
whether they had received care from a psychologist, social or 
pastoral worker, sexologist, physical therapist, lymphedema 
therapist, and dietician and/or whether they were enrolled in 
a rehabilitation program combining physical and cognitive- 
behavioral therapy. Uptake of other types of health care was 
also explored.
 Data analysis
The percentage of missing values ranged from 0 to 11.7%. 
Missing data patterns were examined with Little’s miss-
ing completely at random test with a chi-square statistic 
(p < 0.05), and descriptive analyses, i.e., separate-variance 
t tests, cross tabulations, and a tabulated pattern table. The 
results showed that the data could be assumed to be miss-
ing at random, i.e., missingness was predicted by variables 
that were part of the dataset. Five imputations were gener-
ated for the missing data by the use of the fully conditional 
specification algorithm (non-monotonous data) [30, 31]. The 
variables, referral wish, and referral by the research team 
were not imputed because of the small N for these variables 
and many possible outcomes: imputations were perceived 
as unreliable.
Descriptive statistics were calculated for sociodemo-
graphic and illness-related characteristics, the DT/PL, and 
health care use. Continuing elevated distress was defined 
as a DT score of ≥ 5 at both T1 and T2. Continuing low 
distress was assumed when patients reported a DT score of 
< 5 at both timepoints. Survivors who developed recurrent/
metastasized breast cancer or another malignancy during the 
study period were excluded at T2.
Associations between DT/PL scores and changes herein 
over time (ΔT1–T2) and time since diagnosis and time 
since chemotherapy were calculated by Spearman’s cor-
relations to explore the effect of time on DT/PL responses. 
Chi-square tests and Mann-Whitney U tests were per-
formed to explore univariate effects of sociodemographic 
and illness-related characteristics, health care use (dichoto-
mized (Yes/No), problem domains and problem items at T1 
on continuing elevated distress (patients with a DT score 
of ≥ 5 at both T1 and T2 versus patients with a DT score 
of ≤ 4 at one or both time points). Effect sizes (ES) were 
reported for significant results to examine the clinical rel-
evance (Cramers’s V (V) for chi-square tests; r for Mann-
Whitney U tests). An ES of 0.1 indicates a small effect, 0.3 
a medium effect, and 0.5 a large effect [32, 33]. Statistical 




Seventy-seven of the 91 eligible survivors approached dur-
ing the 1.5 year of the study at the UMCG and agreed to 
participate in the study (response = 84.6%; Fig. 1). The main 
reasons for survivors to decline study participation were a 
lack of interest to talk about their current psychosocial health 
status (N = 7) or they did not feel comfortable discussing 
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psychosocial issues (N = 3). Chemotherapy completion var-
ied between 1.0 and 4.8 years at study entry, and patients 
were on average 3 years after diagnosis (range = 1.6–5.2). 
Fifty-four (74%) patients were receiving hormonal treatment 
at T1; 44 at T2 (60%, Table 1).
 Distress and underlying problems
At T1, 35 survivors (48%) indicated they experienced clini-
cally elevated distress. Twenty-three (32%) reported elevated 
distress at T2. Eighteen survivors (25%) suffered from clini-
cally elevated levels of distress both at T1 and 1 year later. 
Thirty-three (46%) reported low distress at both timepoints 
(Table 2). The top five most often reported problems were 
in the physical and emotional domains (Table 3). Fatigue 
and lack of physical fitness were most often reported at T1 
and T2, both by the complete sample and by survivors expe-
riencing continuing elevated distress. Problems were more 
prevalent in the continuing elevated distress subgroup (e.g., 
fatigue: N = 16/18; 89% (T1)) compared to the complete sam-
ple (fatigue: N = 48/73; 66% (T1)). The number of survivors 
who reported one of the top five problems decreased from 
T1 to T2. At T2, more survivors with continuing elevated 
distress reported tension/nervousness and fears than at T1.
 Variables associated with continuing elevated 
distress versus no continuing elevated distress
Time since diagnosis and time since chemotherapy were 
not related to DT/PL scores at T1 or T2 and DT/PL change 
scores over time. Shorter time since diagnosis was signifi-
cantly related to a higher likelihood of reporting clinically 
Fig. 1 Flow chart of the study
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Table 1 Patient characteristics at T1 and univariate associations with continuing elevated distress (N = 73)
Characteristic Median (IQR) N (%) Test statisticab (p)
Age (years) 52.1 (45.7–56.6) U = 437.8 (0.440)
Marital status
  Single/widowed/divorced 12 (16.4) χ2 = 0.0 (0.967)
  Married/living together 61 (83.6)
Children
  No 21 (28.8)
  Yes 52 (71.2) χ2 = 1.1 (0.292)
Educational level 4.0 (3.0–5.0) U = 491.5 (0.928)
Employment
  Not employed 30 (41.1) χ2 = 3.8 (0.054)
  Employed 43 (58.9)
Stage of cancer
  I 11 (15.1) χ2 = 1.4 (0.495)
  II 49 (67.1)
  III 13 (17.8)
Time since diagnosis (years) 2.8 (2.1–3.7) U = 336.2 (0.040)
Time since chemotherapy completion (years) 2.2 (1.6–3.4) U = 397.0 (0.198)
Surgery
  Lumpectomy 31 (42.5) χ2 = 0.7 (0.406)
  Mastectomy 42 (57.5)
Systemic adjuvant therapy
  Chemotherapy 12 (16.4) χ2 = 6.5 (0.091)
  Chemotherapy and immunotherapy 7 (9.6)
  Chemotherapy and hormonal therapy 45 (61.6)
  Chemotherapy, immunotherapy, and hormonal therapy 9 (12.3)
Hormonal therapy at T1
  No/completed 19 (26.0) χ2 = 0.0 (0.871)
  Yes 54 (74.0)
Hormonal therapy at T2
  No/completeda 29 (39.7) χ2 = 0.0 (0.899)
  Yes 44 (60.3)
Adjuvant radiotherapy
  No 31 (42.5) χ2 = 0.5 (0.488)
  Yes 42 (57.5)
Breast reconstruction
  Between diagnosis and T1
    No 57 (78.1) χ2 = 0.4 (0.509)
    Yes 16 (21.9)
  Between T1 and T2
    No 59 (80.8) χ2 = 0.1 (0.726)
    Yes 14 (19.2)
Health care use
  Between diagnosis and T1
    No 24 (32.9) χ2 = 8.2 (0.004)
    Yes 49 (67.1)
  Between T1 and T2
    No 34 (46.6) χ2 = 5.5 (0.022)
    Yes 39 (53.4)
a Average test result across imputed datasets
b Continuing elevated distress was defined as a DT score of ≥ 5 at both T1 and T2
U, Mann-Whitney U test; X2, chi-square; IQR, interquartile range
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elevated distress at both measurement points, i.e., to experi-
ence continuing elevated distress (Table 1; r = 0.24; small to 
medium ES). Also, survivors who accessed health care ser-
vices between diagnosis and T1 (V = 0.34; medium ES) and/
or between T1 and T2 (V = 0.28; small to medium ES) were 
more likely to report continuing elevated distress (Table 1). 
Survivors who had a higher score on the practical (V = 0.38; 
medium to large ES), social (V = 0.23; small to medium ES), 
emotional (V = 0.33; medium ES), and/or physical (V = 0.47; 
large ES) problem domains at T1 were more likely to indicate 
that they experienced continuing elevated distress (Table 2).
 Referral wish, health care use, and actual referral 
to specific services
Table 4 displays survivors’ health care use, referral wish, 
actual referral at T1 and T2, and uptake of T1 referrals. At 
T1, 27 survivors considered (37%), and eight (11%) had a 
referral wish to a psychosocial and/or paramedical health 
care provider (Table 2). Of these last, two indicated they 
recently started receiving care for their needs. At T2, 12 
considered (17%), and 11 wished (16%) a referral. Two of 
the eleven had recently been referred (Table 4).
Between diagnosis and T1, supportive care was most 
often received from a psychologist (N = 27; 37%) or a physi-
cal therapist/lymphedema therapist (N = 18; 25%). The most 
frequently visited health care providers between T1 and T2 
were the physical/lymphedema therapist (N = 25; 34%)) and 
the psychologist (N = 10; 14%). At T1, ten survivors (14%) 
were referred by the research nurse/psychologist after dis-
cussion of DT/PL responses, most (N = 6) to a psychologist. 
At T2, 11 (16%) survivors indicated having a referral wish 
and six (8% of the total group) were referred after discus-
sion of DT/PL responses, three to a gynecologist/sexologist, 
and three to a psychologist. The one survivor who had been 
referred to a multidimensional rehabilitation program at T1 
actually participated in the program. Of the six survivors 
referred to a psychologist, three actually went. The two sur-
vivors referred to a social worker and the one referred to 
a gynecologist/sexologist did not uptake the care service.
 Discussion
This study was the first that longitudinally assessed the DT/
PL in breast cancer survivors who were 1 to 5 years after 
chemotherapy completion and 19 months to 5 years after 
diagnosis. The findings of the present study are that at least 
one-third of long-term survivors experienced clinically 
elevated distress at one of the time points, and one in four 
survivors reported clinically elevated distress at both time 
points. This proportion lies well above estimates of psycho-
logical morbidity in the general Dutch female population 
(between 10 and 19%; [34]). The percentage of patients with 
continuing elevated distress was somewhat higher than the 
21% that was reported in a recent Dutch study that used the 
Dutch DT/PL and included survivors who were at 15-month 
post- diagnosis [17]. This difference may be explained by the 
treatment modalities survivors received: 63% of survivors in 
the aforementioned study received radiotherapy only whereas 
all survivors in the current study received chemotherapy. 
Patients who (also) receive chemotherapy in contrast to 
Table 2 Descriptives of the DT/PL scores at study entry (T1) and 1 year later (T2), changes over time, and univariate associations between the 
problem domains and continuing elevated distress
T1 T2 Continuing elevated distress
N (%) Median (IQR) N (%) Median (IQR) Test statistic (p)a
DT 4.0 (1.5–6.0) 3.0 (1.0–5.0)
  N scoring ≥ 5 35 (48) 23 (32)
  Elevated distress at T1 and T2 18 (25)
  Low distress at T1 and elevated 
distress at T2
5 (7)
  Elevated distress at T1 and low 
distress at T2
17 (23)
  Low distress at T1 and T2 33 (45)
PL subscales
  Practical (0–70)r 4.0 (0.0–11.5) 0.0 (0.0–8.0) U = 255.4 (0.002)
  Social (0–30)r 0.0 (0.0–5.0) 0.0 (0.0–1.7) U = 371.7 (0.050)
  Emotional (0–100)r 12.0 (3.0–35.0) 9.1 (0.0–22.0) U = 279.7 (0.005)
  Spiritual (0–20)r 0.0 (0.0–0.0) 0.0 (0.0–0.1) U = 440.1 (.297)
  Physical (0–250)r 9.5 (9.5–46.5) 7.5 (15.4–34.0) U = 181.4 (0.000)
r Possible scoring range; aAverage test result across imputed datasets; U, Mann-Whitney U test; IQR, interquartile range
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patients who receive other treatment modalities report higher 
levels of distress [29, 35] and lower emotional functioning 
at least up to 2 years after diagnosis [36]. The current study 
shows that a substantial proportion of breast cancer survivors 
experience clinically elevated levels of distress, even beyond 
the first year after chemotherapy completion.
Fatigue and lack of physical fitness were the most often 
reported problems as was reported previously [17, 28]. 
Also, the finding that emotional problems such as ten-
sion/nervousness and fears were frequently reported was 
in line with previous research. However, the prevalence 
of these problems was high compared to previous studies 
[17, 28], especially for emotional problems: other stud-
ies with the DT/PL reported percentages of 40% or lower 
[17, 28]. This may again be explained by the fact that all 
survivors in the current study received chemotherapy. 
Also, the women in our study were somewhat younger 
(mean = 50.6; median = 52.1) compared to the other stud-
ies (mean = 57 [28]; median = 58 [17]) which may explain 
the higher distress levels [9]. The number of survivors who 
reported physical and emotional problems decreased over 
the 1-year period but the numbers remained substantial. 
Also, a higher score for these problems at study inclusion, 
especially physical problems, increased the likelihood 
that survivors reported continuing elevated distress. Thus, 
problems which underlie distress can endure for years 
after chemotherapy completion in breast cancer survivors. 
Attention of health care professionals to lingering problems 
remains important, even years after chemotherapy as these 
problems and distress may not resolve without additional 
support.
Our findings show that a large proportion of survivors 
was or had been using supportive health care services. 
Notably, the use of a physical/lymphedema therapist 
increased from 25 to 36% over time. First symptoms of 
arm lymphedema may occur up to 3 years after surgery 
[37, 38] and can explain the increase in use of this service. 
Also, specific problems such as a lack of physical fitness 
and a lack of muscle strength, which are highly prevalent 
among survivors in the current study, may have encouraged 
survivors to seek help from a physical therapist. More than 
a third of survivors indicated they had received care from a 
psychologist before they participated in the study. A study 
including all types of German cancer patients reported that 
approximately 30% had used psychotherapy and/or psy-
chological counseling since they got cancer. The authors 
showed that women and patients with symptoms of depres-
sion and anxiety were more likely to use these services [39].
The referral wishes survivors reported and consequent 
referral made by a member of the research team after dis-
cussion of the DT/PL did not always align. This could in 
part be explained by the fact that some survivors recently 
started receiving care for their needs through self-referral. 
More importantly, the discussion of DT/PL responses 
helped survivors to elucidate which problems were most 
troubling and what type of support was (mostly) needed. 
Consequently, the wish to be referred to a professional of 
a certain discipline changed. This result underlines the 
importance of discussing DT/PL responses as is being rec-
ommended in the Dutch guideline on distress management 
[20].
Our study had a number of limitations. The first is the 
small sample size. Therefore, we performed univariate anal-
yses to explore associates of continuing elevated distress. 
Larger samples in future studies are needed to confirm and 
extend the current results. Second, a large variation existed 
between the time of chemotherapy completion and the first 
measurement (between 1 and 5 years after completion). 
However, the survivors seem to be a relatively homogene-
ous group considering the problems and health care use that 
were reported at both time points. Future research measuring 
survivors at fixed time-points during the illness trajectory 
Table 3 Top 5 distress-related problems at study entry (T1) and 1 year later (T2) for the complete sample and for patients with continuing 
elevated distress
T1 T2
Rank Complete sample (%) Distressed survivorsa (%) Complete sample (%) Distressed survivorsa (%)
1 Fatigue (66) Fatigue (89) Fatigue (56) Lack of physical fitness (83)
2 Lack of physical fitness (60) Lack of physical fitness (89) Lack of physical fitness (49) Fatigue (78)
3 Tension/nervousness (58) Lack of muscle strength (78) Tension/nervousness (48) Tension/nervousness (78)
4 Fears (56) Pain (72) Sleeping problems (45) Fears (72)




a Survivors who experienced continuing elevated distress defined as a DT score of ≥ 5 at both T1 and T2
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can more precisely indicate survivors’ distress, problems, 
and health care use at specific time-points after chemother-
apy completion. Finally, due to our study design, we were 
not able to assess whether survivors identified with con-
tinuing elevated distress experienced these levels of distress 
during the entire 1-year study period or at the measurement 
points only nor whether they suffered from elevated distress 
(at any time) during chemotherapy treatment.
Several important strengths can be noted. The cur-
rent study was the first to longitudinally examine DT/PL 
responses in longer-term (breast) cancer survivors, par-
ticularly in those who were treated with chemotherapy as 
they often experience more problems than survivors who 
received other treatment types [9]. Second, we explored 
what problem domains were related to continuing elevated 
distress. One previous study related problem domains to 
distress but had a cross-sectional design and was performed 
in lung cancer patients [40]. Third, to the best of our knowl-
edge, this is the first study that made an attempt to explore 
referral wish as measured with the DT/PL in combination 
with actual referral and uptake.
Considering the substantial proportion of longer-term 
breast cancer survivors who report (continuing) elevated dis-
tress, distress-related problems, and referral wishes, distress 
screening and management remain important in clinical prac-
tice even years after completion of chemotherapy. Physical 
Table 4 Supportive health care service use, referral wish, actual referral by the research team for T1 and T2, and uptake of T1 referrals (N = 73)
Health care use 
between diagnosis 
and T1 (N (%))
Referral wish at 
T1 (N (%))a
Referred by 
research team at 
T1 (N (%))
Health care use
between T1 and T2
(N (%))
Referral wish at T2 
(N (%))ab
Referred by 
research team at 
T2 (N (%))b
No 24 (33) 38 (52) 63 (86) 34 (47) 48 (68) 65 (92)
Maybe 27 (37) 12 (17)
Yes 49 (67) 8 (11) 10 (14) 39 (53) 11 (16) 6 (8)
  From/to 1 provider 33 (45) 5 (7) 10 (14) 30 (41) 7 (10) 6 (8)
  From/to 2 providers 12 (16) 2 (3) 0 (0) 7 (10) 0 (0) 0 (0)
  From/to ≥ 3 providers 4 (6) 1 (1) 0 (0) 3 (4) 4 (6) 0 (0)
Health care typec Continued New uptake
Additional medical or nursing care
  Breast cancer nurse/nurse 
specialist
0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
    Oncology/nurse practitioner 2 (3) 3 (4)
  Gynecologist/sexologist (total) 0 (0) 0 (0) 1 (1) 0 (0) 0 (0) 0 (0) 3 (4)




18 (25) 0 (0) 0 (0) 5 (7) 20 (27) 1 (1) 0 (0)
  Dietician 0 (0) 2 (3) 0 (0) 0 (0) 3 (4) 4 (6) 0 (0)
Psychosocial health care
  Psychologist (total) 27 (37) 7(10) 6 (8) 7 (10) 3 (4) 4 (6) 3 (4)
    Actual uptake of T1 referral 3 out of 6
  Social worker (total) 7 (10) 1 (1) 2 (3) 1 (1) 0 (0) 3 (4) 0 (0)
    Actual uptake of referral at T1 0 out of 2
  Psychiatrist 4 (6) 0 (0) 0 (0) 3 (4) 2 (3) 0 (0) 0 (0)
  Pastoral worker 1 (1) 0 (0) 0 (0) 1 (1) 0 (0) 0 (0) 0 (0)
Other supportive care services
  Multidimensional rehabilitation 
program (total)
11 (15) 0 (0) 1 (1) 0 (0) 4 (6) 0 (0) 0 (0)
    Actual uptake of T1 referral 1 out of 1
  Other type of (supportive) 
health carec
2 (3) 0 (0) 0 (0) 1 (1) 3 (4) 3 (4) 0 (0)
a Survivors who answered “No” and “Maybe” on the referral wish question are taken together
b Answers from 2 survivors on the referral by the research team question are missing; thus N = 71 at T2
cBoth inside and outside the University Medical Center Groningen (UMCG)
dOther types of health care include general practitioner, support from fellow patients, and creative therapy
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problems, especially fatigue and lack of physical fitness, were 
most prevalent and were most strongly related to reporting 
continuing elevated distress. We recommend to pay special 
attention to survivors experiencing these problems, i.e., to 
discuss the impact of these problems on survivors’ lives, to 
inform survivors about the potential health risk of not treating 
these problems, and to discuss possible (self-management) 
strategies for dealing with these distress- underlying problems.
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